Group a streptococcal vaccine candidates: Potential for the development of a human vaccine

Current Topics in Microbiology and Immunology

Volumn 368, Issue , 2013, Pages 207-242

  Henningham, Anna ^a   Gillen, Christine M ^a   Walker, Mark J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ARGININE DEIMINASE; FIBRONECTIN BINDING PROTEIN 54; FIBRONECTIN BINDING PROTEIN A; GROUP A STREPTOCOCCAL VACCINE; M PROTEIN; PROTEIN R29; SPY 0416; STREPTOCOCCAL C5A PEPTIDASE; STREPTOCOCCAL FIBRONECTIN BINDING PROTEIN I; STREPTOCOCCAL FIBRONECTIN BINDING PROTEIN II; STREPTOCOCCAL HEMOPROTEIN RECEPTOR; STREPTOCOCCAL IMMUNOGLOBULIN BINDING PROTEIN 35; STREPTOCOCCAL PROTECTIVE ANTIGEN; STREPTOCOCCAL PYROGENIC EXOTOXIN B; STREPTOCOCCAL SECRETED ESTERASE; STREPTOCOCCUS PYOGENES CELL ENVELOPE PROTEINASE; STREPTOCOCCUS VACCINE; TRIGGER FACTOR; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; CARRIER PROTEIN; OUTER MEMBRANE PROTEIN; STREPTOCOCCAL M PROTEIN;

ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BACTERIAL CELL WALL; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; CROSS REACTION; DISEASE MODEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; GROUP A STREPTOCOCCAL INFECTION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TARGETING; SEROTYPE; STREPTOCOCCUS GROUP A; VACCINATION; ANIMAL; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; REVIEW; STREPTOCOCCUS PYOGENES;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES;

MLCS; MLOWN;

EID: 84892932250     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/82-2012-284     Document Type: Article

References (219)

1. Abdel-Aal AB, Batzloff MR, Fujita Y, Barozzi N, Faria A, Simerska P, Moyle PM, Good MF, Toth I (2008) Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates. J Med Chem 51:167-172
2. Abdel-Aal A-BM, Zaman M, Fujita Y, Batzloff MR, Good MF, Toth I (2010) Design of threecomponent vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components. J Med Chem 53:8041-8046
3. Abdissa A, Asrat D, Kronvall G, Shittu B, Achiko D, Zeidan M, Yamuah LK, Aseffa A (2006) High diversity of group A streptococcal emm types among healthy schoolchildren in Ethiopia. Clin Infect Dis 42:1362-1367
4. Ahmed EA, Penfound TA, Brewer SC, Tennant PA, Chiang EY, Dale JB (2010) Streptococcal protective antigens (Spa): a new family of type-specific proteins of group A streptococci. Eur J Clin Microbiol Infect Dis 29:51-57
5. Ambrosch F, Wiedermann G, Jonas S, Althaus B, Finkel B, Gluck R, Herzog C (1997) Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 15:1209-1213
6. Baldassarri L, Creti R, Recchia S, Imperi M, Facinelli B, Giovanetti E, Pataracchia M, Alfarone G, Orefici G (2006) Therapeutic failures of antibiotics used to treat macrolide-susceptible Streptococcus pyogenes infections may be due to biofilm formation. J Clin Microbiol 44:2721-2727
7. Basma H, Norrby-Teglund A, McGeer A, Low DE, El-Ahmedy O, Dale JB, Schwartz B, Kotb M (1998) Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections. Infect Immun 66:2279-2283
8. Bates CS, Montanez GE, Woods CR, Vincent RM, Eichenbaum Z (2003) Identification and characterization of a Streptococcus pyogenes operon involved in binding of hemoproteins and acquisition of iron. Infect Immun 71:1042-1055
9. Batzloff MR, Hayman WA, Davies MR, Zeng M, Pruksakorn S, Brandt ER, Good MF (2003) Protection against group A streptococcus by immunisation with J8-Diphtheria toxoid: contribution of J8- and Diphtheria toxoid-specific antibodies to protection. J Infect Dis 187:1598-1608
10. Batzloff MR, Yan H, Davies MR, Hartas J, Lowell GH, White G, Burt DS, Leanderson T, Good MF (2005) Toward the development of an anti-disease, transmission-blocking intranasal vaccine for group A streptococcus. J Infect Dis 192:1450-1455
11. Batzloff MR, Hartas J, Zeng W, Jackson DC, Good MF (2006) Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group a streptococcus challenge and reduces throat colonization. J Infect Dis 194:325-330
12. Beachey EH, Seyer JM, Dale JB, Simpson WA, Kang AH (1981) Type-specific protective immunity evoked by synthetic peptide of Streptococcus pyogenes M protein. Nature 292:457-459
13. Beachey EH, Gras-Masse H, Tarter A, Jolivet M, Audibert F, Chedid L, Seyer JM (1986) Opsonic antibodies evoked by hybrid peptide copies of types 5 and 24 streptococcal M proteins synthesized in tandem. J Exp Med 163:1451-1458
14. Beall B, Gherardi G, Lovgren M, Facklam RR, Forwick BA, Tyrrell GJ (2000) emm and sof gene sequence variation in relation to serological typing of opacity-factor-positive group A streptococci. Microbiology 146:1195-1209
15. Bensi G, Mora M, Tuscano G, Biagini M, Chiarot E, Bombaci M, Capo S, Falugi F, Manetti AG, Donato P, Swennen E, Gallotta M, Garibaldi M, Pinto V, Chiappini N, Musser JM, Janulczyk R, Mariani M, Scarselli M, Telford JL, Grifantini R, Norais N, Margarit I, Grandi G (2012) Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case. Mol Cell Proteomics 11:M111.015693
16. Berge A, Sjöbring U (1993) PAM, a novel plasminogen-binding protein from Streptococcus pyogenes. J Biol Chem 268:25417-25424
17. Bessen D, Fischetti VA (1988) Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect Immun 56:2666-2672
18. Bessen D, Fischetti VA (1990) Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes. J Immunol 145:1251-1256
19. Bloomfield AL, Felty AR (1923) Prophylactic vaccination against acute tonsillitis. Johns Hopkins Hosp Bull 34:251-253
20. Bombaci M, Grifantini R, Mora M, Reguzzi V, Petracca R, Meoni E, Balloni S, Zingaretti C, Falugi F, Manetti A G O, Margarit I, Musser JM, Cardona F, Orefici G, Grandi G, Bensi G (2009) Protein array profiling of tic patient sera reveals a broad range and enhanced immune response against Group A Streptococcus antigens. PLoS ONE 4:e6332
21. Brandt ER, Hayman WA, Currie B, Carapetis JR, Wood Y, Jackson DC, Cooper J, Melrose WD, Saul AJ, Good MF (1996) Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Immunology 89:331-337
22. Brandt ER, Hayman WA, Currie B, Pruksakorn S, Good MF (1997) Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. Vaccine 15:1805-1812
23. Brandt ER, Hayman WA, Currie B, Carapetis J, Jackson DC, Do KA, Good MF (1999) Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian Aboriginal endemic communities. Int Immunol 11:569-576
24. Brandt ER, Sriprakash KS, Hobb RI, Hayman WA, Zeng W, Batzloff MR, Jackson DC, Good MF (2000) New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat Med 6:455-459
25. Bronze MS, Courtney HS, Dale JB (1992) Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses. J Immunol 148:888-893
26. Brook I (2007) Overcoming penicillin failures in the treatment of group A streptococcal pharyngotonsillitis. Int J Pediatr Otorhinolaryngol 71:1501-1508
27. Carapetis JR, Steer AC, Mulholland EK, Weber M (2005) The global burden of group A streptococcal diseases. Lancet Infect Dis 5:685-694
28. Carlsson F, Sandin C, Lindahl G (2005) Human fibrinogen bound to Streptococcus pyogenes M protein inhibits complement deposition via the classical pathway. Mol Microbiol 56:28-39
29. Cheng Q, Debol S, Lam H, Eby R, Edwards L, Matsuka Y, Olmsted SB, Cleary PP (2002) Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice. Infect Immun 70:6409-6415
30. Chiang-Ni C, Wang CH, Tsai PJ, Chuang WJ, Lin YS, Lin MT, Liu CC, Wu JJ (2006) Streptococcal pyrogenic exotoxin B causes mitochondria damage to polymorphonuclear cells preventing phagocytosis of group A streptococcus. Med Microbiol Immun 195:55-63
31. Chmouryguina I, Suvorov A, Ferrieri P, Cleary PP (1996) Conservation of the C5a peptidase genes in group A and B streptococci. Infect Immun 64:2387-2390
32. Cleary PP, Handley J, Suvorov AN, Podbielski A, Ferrieri P (1992) Similarity between the group B and A streptococcal C5a peptidase genes. Infect Immun 60:4239-4244
33. Cleary PP, Matsuka YV, Hunyh T, Lam H, Olmsted SB (2004) Immunisation with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice. Vaccine 22:4332-4341
34. Cole JN, Ramirez RD, Currie BJ, Cordwell SJ, Djordjevic SP, Walker MJ (2005) Surface analysis and immune reactivity of major cell-wall associated proteins of group A streptococcus. Infect Immun 73:3137-3146
35. Cole JN, Barnett TC, Nizet V, Walker MJ (2011) Molecular insight into invasive group A streptococcal disease. Nat Rev Microbiol 9:724-736
36. Courtney HS, Li Y, Dale JB, Hasty DL (1994) Cloning, sequencing, and expression of a fibronectin/fibrinogen-binding protein from group A streptococci. Infect Immun 62:3937-3946
37. Courtney HS, Dale JB, Hasty DL (1996) Differential effects of the streptococcal fibronectinbinding protein, FPB54, on adhesion of group A streptococci to human buccal cells and HEp-2 tissue culture cells. Infect Immun 64:2415-2419
38. Courtney HS, Dale JB, Hasty DL (2002) Mapping the fibrinogen-binding domain of serum opacity factor of group A streptococci. Curr Microbiol 44:236-240
39. Courtney HS, Hasty DL, Dale JB (2003) Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci. Infect Immun 71:5097-5103
40. Courtney HS, Li Y, Twal WO, Argraves WS (2009) Serum opacity factor is a streptococcal receptor for the extracellular matrix protein fibulin-1. J Biol Chem 284:12966-12971
41. Cue D, Lam H, Cleary PP (2001) Genetic dissection of the Streptococcus pyogenes M1 protein: regions involved in fibronectin binding and intracellular invasion. Microb Pathog 31:231-242
42. Cunningham MW (2003) Autoimmunity and molecular mimicry in the pathogenesis of poststreptococcal heart disease. Front Biosci 8:s533-543
43. Dale JB (1999) Multivalent group A streptococcal vaccine designed to optomize the immunogenicity of six tandem M protein fragments. Vaccine 17:193-200
44. Dale JB, Beachey EH (1985) Epitopes of streptococcal M proteins shared with cardiac myosin. J Exp Med 162:583-591
45. Dale JB, Seyer JM, Beachey EH (1983) Type-specific immunogenicity of a chemically synthesized peptide fragment of type 5 streptococcal M protein. J Exp Med 158:1727-1732
46. Dale JB, Chiang EY, Lederer JW (1993) Recombinant tetravalent group A streptococcal M protein vaccine. J Immunol 151:2188-2194
47. Dale JB, Simmons M, Chiang EC, Chiang EY (1996) Recombinant, octavalent group A streptococcal M protein vaccine. Vaccine 14:944-948
48. Dale JB, Chiang EY, Liu S, Courtney HS, Hasty DL (1999) New protective antigen of group A streptococci. J Clin Invest 103:1261-1268
49. Dale JB, Penfound TA, Chiang EY, Walton WJ (2011) New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine 29:8175-8178
50. D'Alessandri R, Plotkin G, Kluge RM, Wittner MK, Fox EN, Dorfman A, Waldman RH (1978) Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus. J Infect Dis 138:712-718
51. Degnan BA, Palmer JM, Robson T, Jones C E D, Fischer M, Glanville M, Mellor GD, Diamond AG, Kehoe MA, Goodacre JA (1998) Inhibition of human peripheral blood mononuclear cell proliferation by Streptococcus pyogenes cell extract is associated with arginine deiminase activity. Infect Immun 66:3050-3058
52. Delvecchio A, Currie BJ, McArthur JD, Walker MJ, Sriprakash KS (2002) Streptococcus pyogenes prtFII, but not sfbI, sfbII, or fbp54, is represented more frequently among invasivedisease isolates of tropical Australia. Epidemiol Infect 128:391-396
53. Dinkla K, Rohde M, Jansen W T M, Kaplan EL, Chhatwal GS, Talay SR (2003) Rheumatic fever-associated Streptococcus pyogenes isolates aggregate collagen. J Clin Invest 11:1905-1912
54. Eberhard TH, Sledjeski DD, Boyle MD (2001) Mouse skin passage of a Streptococcus pyogenes Tn917 mutant of sagA/pel restores virulence, beta-hemolysis and sagA/pel expression without altering the position or sequence of the transposon. BMC Microbiol 1:33
55. Edwards RJ, Taylor GW, Ferguson M, Murray S, Rendell N, Wrigley A, Bai Z, Boyle J, Finney SJ, Jones A, Russell HH, Turner C, Cohen J, Faulkner L, Sriskandan S (2005) Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes. J Infect Dis 192:783-790
56. Fischetti V (1989) Streptococcal M protein: molecular design and biological behaviour. Clin Microbiol Rev 2:285-314
57. Fischetti VA (1991) Streptococcal M protein. Sci Am 264:32-39
58. Fischetti VA, Hodges WM, Hruby DE (1989) Protection against streptococcal pharyngeal colonization with a vaccinia: M protein recombinant. Science 244:1487-1490
59. Fisher M, Huang YS, Li X, McIver KS, Toukoki C, Eichenbaum Z (2008) Shr is a broadspectrum surface receptor that contributes to adherence and virulence in group A streptococcus. Infect Immun 76:5006-5015
60. Fontaine MC, Lee JJ, Kehoe MA (2003) Combined contributions of streptolysin O and streptolysin S to virulence of serotype M5 Streptococcus pyogenes strain Manfredo. Infect Immun 71:3857-3865
61. Fox EN, Wittner MK, Dorfman A (1966) Antigenicity of the M proteins of group A hemolytic streptococci. 3. Antibody responses and cutaneous hypersensitivity in humans. J Exp Med 124:1135-1151
62. Fox EN, Waldman RH, Wittner MK, Mauceri AA, Dorfman A (1973) Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers. J Clin Invest 52:1885-1892
63. Fritzer A, Senn BM, Minh DB, Hanner M, Gelbmann D, Noiges B, Henics T, Schulze K, Guzman CA, Goodacre J, von Gabain A, Nagy E, Meinke AL (2010) Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine. Infect Immun 78:4051-4067
64. Fujita Y, Abdel-Aal AB, Wimmer N, Batzloff MR, Good MF, Toth I (2008) Synthesis and immunological evaluation of self-adjuvanting glycolipopeptide vaccine candidates. Bioorg Med Chem 16:8907-8913
65. Georgousakis MM, Hofmann A, Batzloff MR, McMillan DJ, Sriprakash KS (2009) Structural optimisation of a conformational epitope improves antigenicity when expressed as a recombinant fusion protein. Vaccine 27:6799-6806
66. Gillen CM, Courtney HS, Schulze K, Rohde M, Wilson MR, Timmer AM, Guzman CA, Nizet V, Chhatwal GS, Walker MJ (2008) Opacity factor activity and epithelial cell binding by the serum opacity factor protein of Streptococcus pyogenes are functionally discrete. J Biol Chem 283:6359-6366
67. Gladysheva IP, Turner RB, Sazonova IY, Liu L, Reed GL (2003) Coevolutionary patterns in plasminogen activation. Proc Natl Acad Sci USA 100:9168-9172
68. Goldmann O, Chhatwal GS, Medina E (2003) Immune mechanisms underlying host susceptibility to infection with group A streptococci. J Infect Dis 187:854-861
69. Goodfellow AM, Hibble M, Talay SR, Kreikemeyer B, Currie BJ, Sriprakash KS, Chhatwal GS (2000) Distribution and antigenicity of fibronectin binding proteins (SfbI and SfbII) of Streptococcus pyogenes clinical isolates from the Northern Territory, Australia. J Clin Microbiol 38:389-392
70. Gryllos I, Cywes C, Shearer MH, Cary M, Kennedy RC, Wessels MR (2001) Regulation of capsule gene expression by group A Streptococcus during pharyngeal colonization and invasive infection. Mol Microbiol 42:61-74
71. Gryllos I, Grifantini R, Colaprico A, Cary ME, Hakansson A, Carey DW, Suarez-Chavez M, Kalish LA, Mitchell PD, White GL, Wessels MR (2008) PerR confers phagocytic killing resistance and allows pharyngeal colonization by group A Streptococcus. PLoS Pathog 4:e1000145
72. Guilherme L, Faé KC, Higa F, Chaves L, Oshiro SE, Freschi de Barros S, Puschel C, Juliano MA, Tanaka AC, Spina G, Kalil J (2006) Towards a vaccine against rheumatic fever. Clin Dev Immunol 13:125-132
73. Guilherme L, Postol E, Freschi de Barros S, Higa F, Alencar R, Lastre M, Zayas C, Puschel CR, Silva WR, Sa-Rocha LC, Sa-Rocha VM, Pérez O, Kalil J (2009) A vaccine against S. pyogenes: design and experimental immune response. Methods 49:316-321
74. Guzmán CA, Talay SR, Molinari G, Medina E, Chhatwal GS (1999) Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with fibronectin-binding protein SfbI. J Infect Dis 179:901-906
75. Hall MA, Stroop SD, Hu MC, Walls MA, Reddish MA, Burt DS, Lowell GH, Dale JB (2004) Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Infect Immun 72:2507-2512
76. Hanski E, Caparon MG (1992) Protein F, a fibronectin-binding protein is an adhesin of the group A streptococcus Streptococcus pyogenes. Proc Natl Acad Sci USA 89:6172-6176
77. Hayman WA, Brandt ER, Relf WA, Cooper J, Saul A, Good MF (1997) Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol 9:1723-1733
78. Hayman WA, Toth I, Flinn N, Scanlin M, Good MF (2002) Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology. Immunol Cell Biol 80:178-187
79. Henningham A, Chiarot E, Gillen CM, Cole JN, Rohde M, Fulde M, Ramachandran V, Cork AJ, Hartas J, Magor G, Djordjevic SP, Cordwell SJ, Kobe B, Sriprakash KS, Nizet V, Chhatwal GS, Margarit I Y R, Batzloff MR, Walker MJ (2012) Conserved anchorless surface proteins as group A streptococcal vaccine candidates. J Mol Med. 90:1197-1207. doi:10.1007/s00109-012-0897-9
80. Hsu JF, Chuang WJ, Shiesh SC, Lin YS, Liu CC, Wang CC, Fu TF, Tsai JH, Tsai WL, Huang YJ, Hsieh YH, Wu JJ, Lin MT, Huang W (2008) Streptococcal pyrogenic exotoxin B cleaves human S-adenosylhomocysteine hydrolase and induces hypermethioninemia. J Infect Dis 198:367-374
81. Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB (2002) Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 70:2171-2177
82. Huang YS, Fisher M, Nasrawi Z, Eichenbaum Z (2011) Defense from the group a streptococcus by active and passive vaccination with the streptococcal hemoprotein receptor. J Infect Dis 203:1595-1601
83. Hyland KA, Wang B, Cleary PP (2007) Protein F1 and Streptococcus pyogenes resistance to phagocytosis. Infect Immun 75:3188-3191
84. Hytönen J, Haataja S, Gerlach D, Podbielski A, Finne J (2001) The SpeB virulence factor of Streptococcus pyogenes, a multifunctional secreted and cell surface molecule with strepadhesin, laminin-binding and cysteine protease activity. Mol Microbiol 39:512-519
85. Ikebe T, Hirasawa K, Suzuki R, Ohya H, Isobe J, Tanaka D, Katsukawa C, Kawahara R, Tomita M, Ogata K, Endoh M, Okuno R, Tada Y, Okabe N, Watanabe H, Japan WGfB-hSi (2007) Distribution of emm genotypes among group A streptococcus isolates from patients with severe invasive streptococcal infections in Japan, 2001-2005. Epidemiol Infect 135:1227-1229
86. Jadoun J, Ozeri V, Burstein E, Skutelsky E, Hanski E, Sela S (1998) Protein F1 is required for efficient entry of Streptococcus pyogenes into epithelial cells. J Infect Dis 178:147-158
87. Ji Y, Carlson B, Kondagunta A, Cleary PP (1997) Intranasal immunisation with C5a peptidase prevents nasopharyngeal colonisation of mice by the group A Streptococcus. Infect Immun 65:2080-2087
88. Jones KF, Fischetti VA (1988) The importance of the location of antibody binding on the M6 protein for opsonisation and phagocytosis of group A M6 streptococci. J Exp Med 167:1114-1123
89. Kaplan MH, Meyeserian M (1962) An immunological cross-reaction between group A streptococcal cells and human heart tissue. Lancet 1:706-710
90. Kapur V, Topouzis S, Majesky MW, Li LL, Hamrick MR, Hamill RJ, Patti JM, Musser JM (1993) A conserved Streptococcus pyogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin. Microb Pathog 15:327-346
91. Kapur V, Maffei JT, Greer RS, Li LL, Adams GJ, Musser JM (1994) Vaccination with streptococcal extracellular cysteine protease (interleukin-1 beta convertase) protects mice against challenge with heterologous group A streptococci. Microb Pathog 16:443-450
92. Katerov V, Andreev A, Schalén C, Totolian AA (1998) Protein F, a fibronectin-binding protein of Streptococcus pyogenes, also binds human fibrinogen: isolation of the protein and mapping of the binding region. Microbiology 144:119-126
93. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K, Talbot J, Low DE (1999) Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome-a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 28:800-807
94. Kawabata S, Kunitomo E, Terao Y, Nakagawa I, Kikuchi H, Totsuka K-I, Hamada S (2001) Systemic and mucosal immunisations with fibronectin-binding protein FBP54 induce protective immune response against Streptococcus pyogenes challenge in mice. Infect Immun 69:924-930
95. Kawabata S, Tamura Y, Murakami J, Terao Y, Nakagawa I, Hamada S (2002) A novel, anchorless streptococcal surface protein that binds to human immunoglobulins. Biochem Biophys Res Commun 296:1329-1333
96. Koroleva IV, Efstratiou A, Suvorov AN (2002) Structural heterogeneity of the streptococcal C5a peptidase gene in Streptococcus pyogenes. J Bacteriol 184:6384-6386
97. Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC, Wasserman SS, Dale JB (2004) Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults: phase I trial. JAMA 292:709-715
98. Krause RM, Rammelkamp CH Jr (1962) Studies of the carrier state following infection with group A streptococci. II. Infectivity of streptococci isolated during acute pharyngitis and during the carrier state. J Clin Invest 41:575-578
99. Kreikemeyer B, Beckert S, Braun-Kiewnick A, Podbielski A (2002) Group A streptococcal RofA-type global regulators exhibit a strain-specific genomic presence and regulation pattern. Microbiology 148:1501-1511
100. Kuo CF, Lin YS, Chuang WJ, Wu JJ, Tsao N (2008) Degradation of complement 3 by streptococcal pyrogenic exotoxin B inhibits complement activation and neutrophil opsonophagocytosis. Infect Immun 76:1163-1169
101. Kurupati P, Turner CE, Tziona I, Lawrenson RA, Alam FM, Nohadani M, Stamp GW, Zinkernagel AS, Nizet V, Edwards RJ, Sriskandan S (2010) Chemokine-cleaving Streptococcus pyogenes protease SpyCEP is necessary and sufficient for bacterial dissemination within soft tissues and the respiratory tract. Mol Microbiol 76:1197-1387
102. Lancefield RC (1957) Differentiation of group A streptococci with a common R antigen into three serological types, with special reference to the bactericidal test. J Exp Med 106:525-544
103. Lancefield RC, Perlmann GE (1952) Preparation and properties of a protein (R antigen) occurring in streptococci of group A, type 28 and in certain streptococci of other serological groups. J Exp Med 96:83-97
104. Lei B, Liu M-Y, Chesney GL, Musser JM (2004) Identification of new candidate vaccine antigens made by Streptococcus pyogenes: purification and characterisation of 16 putative extracellular lipoproteins. J Infect Dis 189:79-89
105. Lindblad EB (2000) Freund's adjuvants. In: O'Hagan DT (ed) Vaccine adjuvants: preparation methods and research protocols, 1st edn. Human Press, Totowa
106. Liu M, Zhu H, Zhang J, Lei B (2007) Active and passive immunizations with the streptococcal esterase Sse protect mice against subcutaneous infection with group A streptococci. Infect Immun 75:3651-3657
107. Liu M, Zhu H, Li J, Garcia CC, Feng W, Kirpotina LN, Hilmer J, Tavares LP, Layton AW, Quinn MT, Bothner B, Teixeira MM, Lei B (2012) Group A Streptococcus secreted esterase hydrolyzes platelet-activating factor to impede neutrophil recruitment and facilitate innate immune evasion. PLoS Pathog 8:e1002624
108. Luo YH, Kuo CF, Huang KJ, Wu JJ, Lei HY, Lin MT, Chuang WJ, Liu CC, Lin CF, Lin YS (2007) Streptococcal pyrogenic exotoxin B antibodies in a mouse model of glomerulonephritis. Kidney Int 72:716-724
109. Lymbury RS, Olive C, Powell KA, Good MF, Hirst RG, La Brooy JT, Ketheesan N (2003) Induction of autoimmune valvulitis in Lewis rats following immunization with peptides from the conserved region of group A streptococcal M protein. J Autoimmun 20:211-217
110. Lyon WR, Caparon MG (2003) Trigger Factor-mediated prolyl isomerization influences maturation of the Streptococcus pyogenes cysteine protease. J Bacteriol 185:1667-3661
111. Lyon WR, Gibson CM, Caparon MG (1998) A role for trigger factor and an Rgg-like regulator in the transcription, secretion and processing of the cysteine proteinase of Streptococcus pyogenes. EMBO J 17:6263-6275
112. Ma CQ, Li CH, Wang XR, Zeng RH, Yin XL, Feng HD, Wei L (2009) Similar ability of FbaA with M protein to elicit protective immunity against group A Streptococcus challenge in mice. Cell Mol Immunol 6:73-77
113. Mannam P, Jones KF, Geller BL (2004) Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect Immun 72:3444-3450
114. Marouni MJ, Ziomek E, Sela S (2003) Influence of group A streptococcal acid glycoprotein on expression of major virulence factors and internalisation by epithelial cells. Microb Pathog 35:63-72
115. Massell BF, Michael JG, Amezcua J, Siner M (1968) Secondary and apparent primary antibody responses after group A streptococcal vaccination of 21 children. Appl Microbiol 16:509-518
116. Massell BF, Honikman LH, Amezcua J (1969) Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA 207:1115-1119
117. Matsui H, Sekiya Y, Nakamura M, Murayama SY, Yoshida H, Takahashi T, Imanishi K, Tsuchimoto K, Uchiyama T, Sunakawa K, Ubukata K (2009) CD46 transgenic mouse model of necrotizing fasciitis caused by Streptococcus pyogenes infection. Infect Immun 77:4806-4814
118. McArthur J, Medina E, Mueller A, Chin J, Currie BJ, Sriprakash KS, Talay SR, Chhatwal GS, Walker MJ (2004) Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model. Infect Immun 72:7342-7345
119. McLellan DG, Chiang EY, Courtney HS, Hasty DL, Wei SC, Hu MC, Walls MA, Bloom JJ, Dale JB (2001) Spa contributes to the virulence of type 18 group A streptococci. Infect Immun 69:2943-2949
120. McMillan D (2006) StreptAvax (ID Biomedical). Curr Opin Investig Drugs 7:186-190
121. McMillan DJ, Davies MR, Good MF, Sriprakash KS (2004) Immune response to superoxide dismutase in group A streptococcal infection. FEMS Immunol Med Microbiol 40:249-256
122. McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, Baxendale DM, Reddish MA, Hu MC, Stroop SD, Linden J, Fries LF, Vink PE, Dale JB (2005) Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 41:1114-1122
123. Medaglini D, Pozzi G, King TP, Fischetti VA (1995) Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization. Proc Natl Acad Sci USA 92:6868-6872
124. Medina E, Goldmann O, Rohde M, Lengeling A, Chhatwal GS (2001) Genetic control of susceptibility to group A streptococcal infection in mice. J Infect Dis 184:846-852
125. Meinke A, Henics T, Hanner M, Minh DB, Nagy E (2005) Antigenome technology: a novel approach for the selection of bacterial vaccine candidate antigens. Vaccine 23:2035-2041
126. Michos AG, Bakoula CG, Braoudaki M, Koutouzi FI, Roma ES, Pangalis A, Nikolopoulou G, Kirikou E, Syriopoulou VP (2009) Macrolide resistance in Streptococcus pyogenes: prevalence, resistance determinants, and emm types. Diagn Microbiol Infect Dis 64:295-299
127. Molinari G, Talay SR, Valentin-Weigand P, Rohde M, Chhatwal GS (1997) The fibronectinbinding protein of Streptococcus pyogenes, SfbI, is involved in the internalisation of group A streptococci by epithelial cells. Infect Immun 65:1357-1363
128. Molinari G, Chhatwal GS, Sela S, Jadoun J (1999) Role played by the fibronectin-binding protein SfbI (Protein F1) of Streptococcus pyogenes in bacterial internalisation by epithelial cells. J Infect Dis 179:1049-1050
129. Moyle PM, Olive C, Good MF, Toth I (2006a) Method for the synthesis of highly pure vaccines using the lipid core peptide system. J Pept Sci 12:800-807
130. Moyle PM, Olive C, Ho MF, Burgess M, Karpati L, Good MF, Toth I (2006b) Method for the synthesis of multi-epitopic Streptococcus pyogenes lipopeptide vaccines using native chemical ligation. J Org Chem 71:6846-6850
131. Moyle PM, Olive C, Ho MF, Good MF, Toth I (2006c) Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation. J Med Chem 49:6364-6370
132. Neely MN, Pfeifer JD, Caparon M (2002) Streptococcus-zebrafish model of bacterial pathogenesis. Infect Immun 70:3904-3914
133. Nir-Paz R, Korenman Z, Ron M, Michael-Gayego A, Cohen-Poradosu R, Valinsky L, Beall B, Moses AE (2010) Streptococcus pyogenes emm and T types within a decade, 1996-2005: implications for epidemiology and future vaccines. Epidemiol Infect 138:53-60
134. Oehmcke S, Podbielski A, Kreikemeyer B (2004) Function of the fibronectin-binding serum opacity factor of Streptococcus pyogenes in adherence to epithelial cells. Infect Immun 72:4302-4308
135. Okada N, Pentland AP, Falk P, Caparon MG (1994) M protein and protein F act as important determinants of cell-specific tropism of Streptococcus pyogenes in skin tissue. J Clin Invest 94:965-977
136. Okada N, Liszewski MK, Atkinson JP, Caparon M (1995) Membrane cofactor protein (CD46) is a keratinocyte receptor for the M protein of the group A streptococcus. Proc Natl Acad Sci USA 92:2489-2493
137. Okamoto S, Tamura Y, Terao Y, Hamada S, Kawabata S (2005) Systemic immunization with streptococcal immunoglobulin-binding protein Sib 35 induces protective immunity against group A Streptococcus challenge in mice. Vaccine 23:4852-4859
138. Olive C, Clair T, Yarwood P, Good MF (2002a) Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine 20:2816-2825
139. Olive C, Batzloff MR, Horváth A, Wong A, Clair T, Yarwood P, Toth I, Good MF (2002b) A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Infect Immun 70:2734-2738
140. Olive C, Batzloff M, Horváth A, Clair T, Yarwood P, Toth I, Good MF (2003) Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Infect Immun 71:2373-2383
141. Olive C, Batzloff M, Horváth A, Clair T, Yarwood P, Toth I, Good MF (2004) Group A streptococcal vaccine delivery by immunization with a self-adjuvanting M protein-based lipid core peptide construct. Indian J Med Res 119(Suppl):88-94
142. Olive C, Hsien K, Horváth A, Clair T, Taywood P, Toth I, Good MF (2005) Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides. Vaccine 23:2298-2303
143. Olive C, Sun HK, Ho MF, Dyer J, Horváth A, Toth I, Good MF (2006) Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. J Infect Dis 194:316-324
144. Olive C, Schulze K, Sun HK, Ebensen T, Horvath A, Toth I, Guzman CA (2007) Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation. Vaccine 25:1789-1797
145. O'Loughlin RE, Roberson A, Cieslak PR, Lynfield R, Gershman K, Craig A, Albanese BA, Farley MM, Barrett NL, Spina NL, Beall B, Harrison LH, Reingold A, Van Beneden C, Team A B C S (2007) The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 45:853-862
146. Olsen RJ, Watkins ME, Cantu CC, Beres SB, Musser JM (2011) Virulence of serotype M3 Group A Streptococcus strains in wax worms (Galleria mellonella larvae). Virulence 2:111-119
147. Pandey M, Sekuloski S, Batzloff MR (2009a) Novel strategies for controlling Streptococcus pyogenes infection and associated diseases: from potential peptide vaccines to antibody immunotherapy. Immunol Cell Biol 87:391-399
148. Pandey M, Batzloff M, Good MF (2009b) Mechanism of protection induced by group A Streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection. PLoS ONE 4:e5147
149. Pandiripally V, Gregory E, Cue D (2002) Acquisition of regulators of complement activation by Streptococcus pyogenes serotype M1. Infect Immun 70:6206-6214
150. Park HS, Cleary PP (2005) Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect Immun 73:7878-7886
151. Park H-S, Francis KP, Yu J, Cleary PP (2003) Membranous cells in nasal-associated lymphoid tissue: a portal of entry for the respiratory mucosal pathogen group A Streptococcus. J Immunol 171:2532-2537
152. Perez-Casal J, Okada N, Caparon MG, Scott JR (1995) Role of the conserved C-repeat region of the M protein of Streptococcus pyogenes. Mol Microbiol 15:907-916
153. Pichichero ME, Casey JR (2007) Systematic review of factors contributing to penicillin treatment failure in Streptococcus pyogenes pharyngitis. Otolaryngol Head Neck Surg 137:851-857
154. Piepmeier E Jr, Hammett-Stabler C, Price M, Peters J, Kemper G, Davis M Jr (1995) Myositis and fasciitis associated with group A beta hemolytic streptococcal infections: development of a rabbit model. J Lab Clin Med 126:137-143
155. Pizza M, Scarlato V, Masignani V, Guiliani MM, Aricó B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, Galeotti CL, Luzzi E, Manetti R, Marchetti E, Mora M, Nuti S, Ratti G, Santini L, Savino S, Scarselli M, Storni E, Zuo P, Broeker M, Hundt E, Knapp B, Blair E, Mason T, Tettelin H, Hood DW, Jefferies AC, Saunders NJ, Granoff DM, Venter JC, Moxon ER, Grandi G, Rappouli R (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287:1816-1820
156. Polly SM, Waldman RH, High P, Wittner MK, Dorfman A (1975) Protective studies with a group A streptococcal M protein vaccine. II. Challenge of Volunteers after local immunization in the upper respiratory tract. J Infect Dis 131:217-224
157. Potter EV, Stollerman GH, Siegel AC (1962) Recall of type specific antibodies in man by injections of streptococcal cell walls. J Clin Invest 41:301-310
158. Prakash K, Dutta S (1991) Antibodies to streptococcal opacity factor in a selected Indian population. J Med Microbiol 34:119-124
159. Pruksakorn S, Galbraith A, Houghten RA, Good MF (1992) Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies. J Immunol 149:2729-2735
160. Pruksakorn S, Currie BJ, Brandt ER, Martin D, Galbraith A, Phornphutkul C, Hunsakunachal S, Manmontri A, Good MF (1994) Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci. Lancet 344:639-642
161. Purushothaman SS, Park H, Cleary PP (2004) Promotion of fibronectin independent invasion by C5a peptidase into epithelial cells in group A Streptococcus. Indian J Med Res 119(Suppl):44-47
162. Rakonjac JV, Robbins JC, Fischetti VA (1995) DNA sequence of the serum opacity factor of group A streptococci: identification of a fibronectin-binding repeat domain. Infect Immun 63:622-631
163. Rantz LA, Randall E, Rantz HH (1949) Immunization of human beings with group A hemolytic streptococci. Am J Med 6:424-432
164. Richter SS, Heilmann KP, Beekmann SE, Miller NJ, Miller AL, Rice CL, Doern CD, Reid SD, Doern GV (2005) Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 41:599-608
165. Ringdahl U, Sjöbring U (2000) Analysis of plasminogen-binding M proteins of Streptococcus pyogenes. Methods 21:143-150
166. Rodreiguez-Ortega MJ, Norais N, Bensi G, Liberatori S, Capo S, Mora M, Scarselli M, Doro F, Ferrari G, Garaguso I, Maggi T, Neumann A, Covre A, Telford JL, Grandi G (2006) Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 24:191-197
167. Sabharwal H, Michon F, Nelson D, Wealing D, Fuchs K, Manjarrez RC, Sarkar A, Uitz C, Viteri-Jackson A, Suarez R S R, Blake MS, Zabriskie JB (2006) Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection. J Infect Dis 193:129-135
168. Saetre T, Hoiby EA, Aspelin T, Lermark G, Lyberg T (2000) Acute serogroup A streptococcal shock: a porcine model. J Infect Dis 182:133-141
169. Sanderson-Smith M, Batzloff MR, Sriprakash KS, Dowton M, Ranson M, Walker MJ (2006) Divergence in the plasminogen-binding group a streptococcal M protein family: functional conservation of binding site and potential role for immune selection of variants. J Biol Chem 281:3217-3226
170. Sanderson-Smith M, Dinkla K, Cole JN, Cork AJ, Maamary PG, McArthur J, Chhatwal GS, Walker MJ (2008) M protein-mediated plasminogen binding is essential for the virulence of an invasive Streptococcus pyogenes isolate. FASEB J 22:2715-2722
171. Schmidtchen A, Frick IM, Andersson E, Tapper H, Björck L (2002) Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol Microbiol 46:157-168
172. Schulze K, Guzman CA (2003) Identification of the domains of the fibronectin-binding protein I of Streptococcus pyogenes responsible for adjuvanticity. FEMS Immunol Med Microbiol 37:173-177
173. Schulze K, Medina E, Talay SR, Towers RJ, Chhatwal GS, Guzman CA (2001) Characterization of the domain of fibronectin-binding protein I of Streptococcus pyogenes responsible for elicitation of a protective immune response. Infect Immun 69:622-625
174. Schulze K, Medina E, Chhatwal GS, Guzman CA (2003) Stimulation of long-lasting protection against Streptococcus pyogenes after intranasal vaccination with non adjuvanted fibronectinbinding domain of the SfbI protein. Vaccine 21:1958-1964
175. Schulze K, Medina E, Guzman CA (2006) Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain. Vaccine 24:1446-1450
176. Severin A, Nickbarg E, Wooters J, Quazi SA, Matsuka YV, Murphy E, Moutsatsos IK, Zagursky RJ, Olmsted SB (2007) Proteomic analysis and identification of Streptococcus pyogenes surface-associated proteins. J Bacteriol 189:1514-1522
177. Shet A, Kaplan EL, Johnson DR, Cleary PP (2003) Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development. J Infect Dis 188:809-817
178. Shet A, Kaplan E, Johnson D, Cleary PP (2004) Human immunogenicity studies on group A streptococcal C5a peptidase (SCPA) as a potential vaccine against group A streptococcal infections. Indian J Med Res119(Suppl):95-98
179. Siegel AC, Johnson EE, Stollerman GH (1961) Controlled studies of streptococcal pharyngitis in a pediatric population 1. Factors related to the attack of rheumatic fever. New Engl J Med 265:559-566
180. Siegert J, Sastalla I, Chhatwal GS, Medina E (2006) Vaccination equally enables both genetically susceptible and resistant mice to control infection with group A streptococci. Microb Infect 8:347-353
181. Simerska P, Abdel-Aal AB, Fujita Y, Moyle PM, McGeary RP, Batzloff MR, Olive C, Good MF, Toth I (2008a) Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines. J Med Chem 51:1447-1452
182. Simerska P, Abdel-Aal AB, Fujita Y, Batzloff MR, Good MF, Toth I (2008b) Synthesis and in vivo studies of carbohydrate-based vaccines against group A streptococcus. Biopolymers 90:616-911
183. Sitkiewicz I, Nagiec MJ, Sumby P, Butler SD, Cywes-Bentley C, Musser JM (2006) Emergence of a bacterial clone with enhanced virulence by acquisition of a phage encoding a secreted phospholipase A2. Proc Natl Acad Sci USA 103:16009-16014
184. Skinner JM, Caro-Aguilar IC, Payne AM, Indrawati L, Fontenot J, Heinrichs JH (2011) Comparison of rhesus and cynomolgus macaques in a Streptococcus pyogenes infection model for vaccine evaluation. Microb Pathog 50:39-47
185. Stafslien DK, Cleary PP (2000) Characterisation of the streptococcal C5a peptidase using a C5agreen fluorescent protein fusion protein substrate. J Bacteriol 182:3254-3258
186. Stalhammar-Carlemalm M, Areschoug T, Larsson C, Lindahl G (1999) The R28 protein of Streptococcus pyogenes is related to several group B streptococcal surface proteins, confers protective immunity and promotes binding to human epithelial cells. Mol Microbiol 33:208-219
187. Stalhammar-Carlemalm M, Areschoug T, Larsson C, Lindahl G (2000) Cross-protection between group A and group B streptococci due to cross-reacting surface proteins. J Infect Dis 182:142-149
188. Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR (2009) Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis 9:611-616
189. Stockbauer KE, Magoun L, Liu M, Burns E H J, Gubba S, Renish S, Pan X, Bodary SC, Baker E, Coburn J, Leong JM, Musser JM (1999) A natural variant of the cysteine protease virulence factor of group A Streptococcus with an arginine-glycine-aspartic acid (RGD) motif preferentially binds human integrins aVb3 and aIIbb3. Proc Natl Acad Sci USA 96:242-247
190. Sumby P, Barbian KD, Gardener DJ, Whitney AR, Welty DM, Long RD, Bailey JR, Parnell MJ, Hoe NP, Adams GG, De Leo FR, Musser JM (2005) Extracellular deoxyribonuclease made by group A Streptococcus assists pathogenesis by enhancing evasion of the innate immune response. Proc Natl Acad Sci USA 102:1679-1684
191. Sumby P, Tart AH, Musser JM (2008) A non-human primate model of acute group a Streptococcus pharyngitis. Methods Mol Biol 431:255-267
192. Sun H, Ringdahl U, Homeister JW, Fay WP, Engelberg NC, Yang AY, Rozek LS, Wang X, Sjöbring U, Ginsburg D (2004) Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 305:1283-1286
193. Talay SR, Valentin-Weigand P, Jerlstrom PG, Timmis KN, Chhatwal GS (1992) Fibronectinbinding protein of Streptococcus pyogenes: sequence of the binding domain involved in adherence of streptococci to epithelial cells. Infect Immun 60:3837-3844
194. Terao Y, Kawabata S, Kunitomo E, Murakami J, Nakagawa I, Hamada S (2001) Fba, a novel fibronectin-binding protein from Streptococcus pyogenes, promotes bacterial entry into epithelial cells, and the fba gene is positively transcribed under the Mga regulator. Mol Microbiol 42:75-86
195. Terao Y, Okamoto S, Kataoka K, Hamada S, Kawabata S (2005) Protective immunity against Streptococcus pyogenes challenge in mice after immunization with fibronectin-binding protein. J Infect Dis 192:2081-2091
196. Terao Y, Mori Y, Yamaguchi M, Shimizu Y, Ooe K, Hamada S, Kawabata S (2008) Group A streptococcal cysteine protease degrades C3 (C3b) and contributes to evasion of innate immunity. J Biol Chem 283:6253-6260
197. Timmer AM, Kristian SA, Datta V, Jeng A, Gillen CM, Walker MJ, Beall B, Nizet V (2006) Serum opacity factor promotes group A streptococcal epithelial cell invasion and virulence. Mol Microbiol 62:15-25
198. Tsai PJ, Kuo CF, Lin KY, Lin YS, Lei HY, Chen FF, Wang JR, Wu JJ (1998) Effect of group A streptococcal cysteine protease on invasion of epithelial cells. Infect Immun 66:1460-1466
199. Tsao N, Tsai WH, Lin YS, Chuang WJ, Wang CH, Kuo CF (2006) Streptococcal pyrogenic exotoxin B cleaves properdin and inhibits complement-mediated opsonophagocytosis. Biochem Biophys Res Commun 339:779-784
200. Tse H, Bao J Y J, Davies MR, Maamary PG, Tsoi H, Tong A H Y, Ho T C C, Lin CF, Gillen CM, Barnett TC, Chen HK, Lee M, Yam W, Wong C, Ong CY, Chan Y, Wu C, Ng T, Lim W W L, Tsang T H F, Tse C W S, Dougan G, Walker MJ, Lok S, Yuen K (2012) Molecular characterization of the 2011 Hong Kong scarlet fever outbreak. J Infect Dis 206:341-351
201. Turner CE, Kurupatia P, Wilesa S, Edwards RJ, Sriskandan S (2009) Impact of immunization against SpyCEP during invasive disease with two streptococcal species: Streptococcus pyogenes and Streptococcus equi. Vaccine 27:4923-4929
202. Ulrich RG (2008) Vaccine based on a ubiquitous cysteinyl protease and streptococcal pyrogenic exotoxin A protects against Streptococcus pyogenes sepsis and toxic shock. J Immune Based Ther Vaccines 6:8
203. Vajdy M, Singh M (2005) The role of adjuvants in the development of mucosal vaccines. Expert Opin Biol Ther 5:953-965
204. Virtaneva K, Graham MR, Porcella SF, Hoe NP, Su H, Graviss EA, Gardner TJ, Allison JE, Lemon WJ, Bailey JR, Parnell MJ, Musser JM (2003) Group A Streptococcus gene expression in humans and cynomolgus macaques with acute pharyngitis. Infect Immun 71:2199-2207
205. Virtaneva K, Porcella SF, Graham MR, Ireland RM, Johnson CA, Ricklefs SM, Babar I, Parkins LD, Romero RA, Corn GJ, Gardner DJ, Bailey JR, Parnell MJ, Musser JM (2005) Longitudinal analysis of the group A Streptococcus transcriptome in experimental pharyngitis in cynomolgus macaques. Proc Natl Acad Sci USA 102:9014-9019
206. Von Pawel-Rammingen U, Björck L (2003) IdeS and SpeB: immunoglobulin-degrading cysteine proteinases of Streptococcus pyogenes. Curr Opin Microbiol 6:50-55
207. Waldman RH, Lee JD, Polly SM, Dorfman A, Fox EN (1975) Group A streptococcal M protein vaccine: protection following immunization via the respiratory tract. Dev Biol Stand 28:429-434
208. Wasson VP, Brown EE (1943) Immunization against rheumatic fever. J Pediatr 23:24-30
209. Watson RF, Rothbard S, Swift HF (1946) Type-specific protection and immunity following intranasal inoculation of monkeys with group A hemolytic streptococci. J Exp Med 84:127-142
210. Wilson MG, Swift HF (1931) Intravenous vaccination with hemolytic streptococci. Am J Dis Child 42:42-51
211. Wizemann TM, Adamou JE, Langermann S (1999) Adhesins as targets for vaccine development. Emerging Infect Dis 5:395-403
212. Yokoyama Y, Harabuchi T (2002) Intranasal immunization with lipoteichoic acid and cholera toxin evokes specific pharyngeal IgA and systemic IgG responses and inhibits streptococcal adherence to pharyngeal epithelial cells in mice. Int J Pediatr Otorhinolaryngol 63:235-241
213. Young DC, Breese BB, Errington AF, Stoeffler W (1946) Failure of type specific Streptococcus pyogenes vaccine to prevent respiratory infections. US Nav Med Bull 46:709-718
214. Young MH, Aronoff DM, Engleberg NC (2005) Necrotizing fasciitis: pathogenesis and treatment. Expert Rev Anti Infect Ther 3:279-294
215. Zaman M, Abdel-Aal AB, Phillipps KS, Fujita Y, Good MF, Toth I (2010) Structure-activity relationship of lipopeptide Group A streptococcus (GAS) vaccine candidates on toll-like receptor 2. Vaccine 28:2243-2248
216. Zaman M, Skwarczynski M, Malcolm JM, Urbani CN, Jia Z, Batzloff MR, Good MF, Monteiro MJ, Toth I (2011) Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine. Nanomedicine 7:168-173
217. Zaman M, Abdel-Aal AB, Fujita Y, Phillipps KS, Batzloff MR, Good MF, Toth I (2012) Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structureactivity relationship. PLoS ONE 7:e30146
218. Zhu H, Liu M, Sumby P, Lei B (2009) The secreted esterase of group a streptococcus is important for invasive skin infection and dissemination in mice. Infect Immun 77:5225-5232
219. Zimmerman RA, Krushak DH, Wilson E, Douglas JD (1970) Human streptococcal disease syndrome compared with observations in chimpanzees. II. Immunologic responses to induced pharyngitis and the effect of treatment. J Infect Dis 122:280-289